Compare RGEN & AU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | AU |
|---|---|---|
| Founded | 1981 | 1944 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 49.5B |
| IPO Year | 1995 | 2023 |
| Metric | RGEN | AU |
|---|---|---|
| Price | $176.46 | $113.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $167.67 | $119.00 |
| AVG Volume (30 Days) | 971.2K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 3.94% |
| EPS Growth | ★ 286.96 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $141,236,000.00 | N/A |
| Revenue This Year | $14.30 | $38.71 |
| Revenue Next Year | $14.52 | $2.89 |
| P/E Ratio | $758.46 | ★ $23.93 |
| Revenue Growth | ★ 35.10 | N/A |
| 52 Week Low | $100.99 | $56.62 |
| 52 Week High | $188.73 | $129.14 |
| Indicator | RGEN | AU |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 71.14 |
| Support Level | $156.65 | $76.14 |
| Resistance Level | $188.73 | $129.14 |
| Average True Range (ATR) | 6.21 | 3.50 |
| MACD | 0.29 | 1.56 |
| Stochastic Oscillator | 62.11 | 81.58 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).